文献速递血管炎

评估儿童期起病的抗中性粒细胞胞质抗体相关性血管炎的肾脏疾病:病程、结局及结局预测因素

Evaluating Renal Disease in Pediatric-Onset Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Disease Course, Outcomes, and Predictors of Outcome.
PubMed 文献 · Arthritis Rheumatol · 2025-01-14

该研究基于儿童血管炎登记数据库,纳入145例儿童期起病、有肾脏受累的抗中性粒细胞胞质抗体相关性血管炎患者,评估12个月肾脏结局及诊断时肾功能对结局的预测作用。12个月时83%达到肾脏疾病不活动,但42%存在永久性肾损伤证据。诊断时肾功能中重度下降或肾衰竭者12个月处于非正常KDIGO分期的比值比分别为8.62和26.3。

要点

  • 12个月时83%患者达到肾脏疾病不活动,但42%存在永久性肾损伤证据。
  • 诊断时肾功能中重度下降者12个月非正常KDIGO分期的OR为8.62(P=0.002)。
  • 诊断时肾衰竭者12个月非正常KDIGO分期的OR为26.3(P<0.001)。

核心结论

  • 多数儿童期起病AAV患者12个月时达到肾脏疾病不活动,但近半数存在肾损伤证据。
  • 诊断时肾功能是12个月肾功能状态的强预测因素。

研究设计与样本

  • 采用儿童血管炎登记/儿童血管炎倡议登记(ARChiVe/PediVAS)的回顾前瞻性数据。
  • 纳入145例诊断时≤18岁、诊断为GPA、MPA或ANCA阳性寡免疫复合物肾小球肾炎且有肾脏疾病(经活检或依赖透析定义)的患者。
  • 患者需有诊断时及12或24个月时的临床数据。
  • 主要结局为12个月时肾脏疾病不活动(儿童血管炎活动性评分=0或1)。
  • 次要结局包括24个月内肾功能改善率和损伤率。

主要发现

  • 共纳入145例患者,68%为女性,78%为GPA。
  • 12个月时83%的患者达到肾脏疾病不活动,但42%存在永久性肾损伤证据。
  • 与诊断时肾功能正常者相比,诊断时肾功能中重度下降者12个月处于非正常KDIGO分期的OR为8.62(P=0.002;95%CI 2.31-32.1)。
  • 与诊断时肾功能正常者相比,诊断时肾衰竭者12个月处于非正常KDIGO分期的OR为26.3(P<0.001;95%CI 6.32-109)。

关键数值与推荐

  • 肾脏疾病不活动定义为儿童血管炎活动性评分=0或1。
  • 肾功能以估算肾小球滤过率定义,按KDIGO分期在诊断时分类。
  • 诊断时肾功能中重度下降者12个月非正常KDIGO分期的OR为8.62(P=0.002;95%CI 2.31-32.1)。
  • 诊断时肾衰竭者12个月非正常KDIGO分期的OR为26.3(P<0.001;95%CI 6.32-109)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We aimed to study the disease course, outcomes, and predictors of outcome in pediatric-onset antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) affecting the kidneys. METHODS: Patients eligible for this study had a diagnosis of granulomatosis with polyangiitis (GPA), microscopic polyangiitis, or ANCA-positive pauci-immune glomerulonephritis, were 18 years or younger at diagnosis, had renal disease defined by biopsy or dialysis dependence, and had clinical data at diagnosis and at either 12 or 24 months. Ambispective data from A Registry for Children with Vasculitis/Pediatric Vasculitis Initiative Registry was used. The primary outcome was inactive renal disease (pediatric vasculitis activity score = 0 or 1) at 12 months. Secondary outcomes included rates of improved renal function and damage within 24 months. Renal function, defined by estimated glomerular filtration rate, was categorized into Kidney Disease Improving Global Outcomes (KDIGO) stages at diagnosis and tested as a predictor of outcome using a proportional-odds logistic regression model. RESULTS: A total of 145 patients were included: 68% were female, and 78% had GPA. At 12 months, 83% of patients achieved inactive renal disease; however, 42% had evidence of permanent renal damage. Compared with patients with normal renal function at diagnosis, patients with moderate to severely reduced renal function, or kidney failure at diagnosis, had an odds ratio of 8.62 (P = 0.002; 95% confidence interval [CI] 2.31-32.1) and 26.3 (P < 0.001; 95% CI 6.32-109), respectively, for being in a non-normal KDIGO category at 12 months. CONCLUSION: The majority of patients with pediatric AAV achieve inactive renal disease by 12 months; however, almost half have evidence of damage. Renal function at diagnosis is a strong predictor of renal function at 12 months.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Toor KK, Chen A, Cabral DA, et al. Evaluating Renal Disease in Pediatric-Onset Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Disease Course, Outcomes, and Predictors of Outcome. Arthritis Rheumatol. 2025. PMID: 39624015. doi:10.1002/art.43071

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。